En Es
Categories

Industry News

Companies with Lab-Developed Tests Raise USD 2 Billion

By Labmedica International staff writers
11 Oct 2017

Image: Companies with laboratory-developed tests are attracting increasing investor interest and raised over USD 2 billion between January and August 2017 (Photo courtesy of iStock).Companies with laboratory-developed tests (LTDs), tests performed by laboratories owned by IVD companies and others, are attracting increasing investor interest and raised over USD 2 billion between January and August 2017. These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

LDTs, also called as "home-brew tests" or "in-house tests" were historically low-volume, simple and well-characterized tests for low-risk diagnostic applications. However, in recent years, there has been increased focus and attention on the emergence and growing use of complex LDTs based on technologies such as polymerase chain reaction (PCR), microarrays, next generation sequencing, or other complex technology. High-risk, complex tests have now been developed as LDTs in order to provide clinical results to physicians and their patients.

Presently, LDTs are being used for complex testing which smaller laboratories are not equipped or do not choose to handle and are used for a variety of medical conditions. There are all types of LDTs, including histology and molecular testing to immunoassays; or equipment-intensive testing such as mass spectrometry or flow cytometry. The largest segments of the LDTs market are oncology, genetic (inherited) disorders, and infectious disease, although these tests can be developed and used for virtually all types of disorders.

The significant activity in the development of new LDTs, increasing revenues from current LDTs, and the large addressable markets for several emerging LDTs has attracted the interest of investors as well as of other companies looking for acquisitions. For instance, in 2016, the companies included in Kalorama’s report raised over USD 750 million, although this amount was much smaller in comparison to the over USD 2 billion raised between January and August 2017.

The LDTs market has also witnessed a significant number of acquisitions in recent years, with the major companies making several acquisitions to achieve their current market positions, while smaller clinical laboratories have also been making acquisitions. A number of new companies also continue to be founded, thus providing a continuous stream of smaller companies trying to achieve growth, which may come through acquisitions or they may end up being acquired. Hence, consolidation among companies and laboratories offering LDTs is expected to continue in the future.

Related Links:
Kalorama Information



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

17 Oct 2017
Ortho Clinical Diagnostics and EKF Diagnostics Collaborate for Assay
Ortho Clinical Diagnostics and EKF Diagnostics have entered into an agreement that allows Ortho customers to access the Beta-Hydroxybutyrate (BHB) assay, an important marker used in conjunction with clinical findings and other lab tests for the diagnosis and management of ketoacidosis and its main causative factor, diabetic ketoacidosis (DKA). The fully automated assay is now available for use on Ortho's VITROS 4600 chemistry system and the VITROS 5600 integrated system.
Read More
16 Oct 2017
Release of X-Ray Database to Boost AI Research
The U.S. National Institutes of Health (NIH) recently made available a massive database of chest X-rays, marking a huge step toward integrating artificial intelligence (AI) mechanisms into clinical practice.
Read More
16 Oct 2017
BioVendor Acquires All Shares of DIAsource ImmunoAssays SA
BioVendor - Laboratornímedicínaa.s., an international diagnostics holding, has acquired 100% of the shares of DIAsourceImmunoAssays SA from Anteo Diagnostics, which had acquired DIAsource in January 2016.
Read More
16 Oct 2017
Handheld Scanners Market to Reach USD 725 Million by 2027
The global handheld ultrasound scanners market is projected to grow at a robust CAGR of 8.8% from around USD 311 million in 2017 to about USD 725 million by 2027 end, driven mainly by the increasing use of handheld ultrasound scanners among non-radiologists and modernization in healthcare, coupled with high investment in research and development (R&D).
Read More
16 Oct 2017
Siemens Healthineers Enters Agreement with HORIBA Medical
Siemens Healthineers and HORIBA Medical have entered into a long-term agreement to bring new and innovative hematology solutions to the market globally.
Read More
11 Oct 2017
Abbott Closes Acquisition of Alere
Abbott has closed the acquisition of Alere, Inc., following the receipt of all regulatory clearances required for the closing.
Read More
10 Oct 2017
IBM Watson Uses AI to Determine Patients Who Need Contrast
Researchers at the University of California, San Francisco (UCSF) have discovered that IBM Watson can help optimize the process of determining which patients need contrast for musculoskeletal MRI scans.
Read More
10 Oct 2017
Toshiba to Change Name to Canon in January
Toshiba Medical Systems Corporation will change its company name to Canon Medical Systems Corporation on January 4, 2018. The decision by Toshiba Medical to change the company’s name comes after it officially became a subsidiary of Canon Inc. in December 2016.
Read More
09 Oct 2017
Top Trends Impacting Global POC Testing Market
The global point-of-care (POC) HbA1C testing market is projected to grow at a CAGR of almost 9% from 2017-2021, driven mainly by the unhealthy lifestyles of people resulting in increased prevalence of diabetes and obesity, easy patient accessibility to POC tests and faster availability of results as compared to conventional laboratory testing procedures.
Read More
Copyright © 2000-2017 TradeMed.com. All rights reserved. | Terms And Conditions